U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 0.4% on Tuesday.The Dow traded up 0.39% to 47,731.04 while the NASDAQ rose 0.42% to 23,736.30. The S&P 500 also rose, gaining, 0.07% to 6,879.97.Check This Out: Top 3 Consumer Stocks Which Could Rescue Your Portfolio In Q4Leading and Lagging SectorsInformation technology shares jumped by 0.7% on Tuesday.In trading on Tuesday, real estate stocks fell by 1.6%.Top HeadlinePayPal Holdings Inc. (NASDAQ:PYPL) stock jumped a ...

Oct 28, 2025 12:03 PM Eastern Daylight Time Law Offices of Frank R. Cruz Encourages MoonLake Immunotherapeutics (MLTX) Shareholders to Inquire About Securities Fraud Class Action Share LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased MoonLake Immunotherapeutics ("MoonLake†or the "Company†) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the "Class Period†). M ...

Key Points Management's medium-term sales target for its Zoryve franchise pleased investors. Its near-term sales estimate for 2026 also blasted past analyst estimates. 10 stocks we like better than Arcutis Biotherapeutics › Shares in Arcutis Biotherapeutics (NASDAQ: ARQT) soared by almost 30% in trading to 10:30 a.m. ET today. The move comes after an excellent set of third-quarter earnings and an investor day presentation replete with positive near- and medium-term guidance that exceeded analyst ex ...

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) is a leading biotech company, headquartered in Boston, MA, that specializes in tackling serious conditions. They have brought to market several transformative treatments for cystic fibrosis (CF), sickle cell disease (SCD), transfusion-dependent beta thalassemia (TDT), and chronic/acute pain, and areI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend re ...

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) is a leading biotech company, headquartered in Boston, MA, that specializes in tackling serious conditions. They have brought to market several transformative treatments for cystic fibrosis (CF), sickle cell disease (SCD), transfusion-dependent beta thalassemia (TDT), and chronic/acute pain, and areI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend re ...

BREAKING: Stocks Rumble Higher As PayPal, UnitedHealth RallyArcutis Biotherapeutics (ARQT) smashed third-quarter expectations Tuesday and reported its first-ever positive net income, leading Arcutis stock to skyrocket.In late morning trades, Arcutis stock surged more than 24% to 24.49. Shares topped a profit-taking zone after, last month, breaking out of a cup base.The company makes Zoryve, a cream that treats skin conditions like psoriasis and eczema. During the third quarter, Zoryve generated $99.2 millio ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Points - Genprex, Inc. has announced a registered direct offering of 377,780 shares of common stock at a price of $9.00 per share, with potential additional gross proceeds of up to $6.6 million from short-term warrants [1][2] - The offering is expected to close around October 29, 2025, subject to customary closing conditions [1] - H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering [2] Financial Details - The gross proceeds from the offering are anticipated to be approximately $3.4 million before deducting fees and expenses [2] - The short-term warrants will allow the purchase of up to 755,560 shares at an exercise price of $8.75 per share, which will be immediately exercisable [1][2] Regulatory Information - The shares are being offered under a "shelf" registration statement that was declared effective by the SEC on June 9, 2023 [3] - The unregistered warrants and underlying shares are being offered in a private placement and have not been registered under the Securities Act [4] Company Overview - Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes [6] - The company's lead product candidate, Reqorsa® Gene Therapy, is being evaluated in clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [7] - Genprex's diabetes gene therapy approach aims to transform pancreatic alpha cells into functional beta-like cells to produce insulin [7]

Wall Street expects a year-over-year increase in earnings on higher revenues when Rhythm Pharmaceuticals, Inc. (RYTM) reports results for the quarter ended September 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on November 4, might help the stock move higher if these key numbers are ...

Shares of Tvardi Therapeutics (TVRD) have been struggling lately and have lost 21.1% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish cas ...